Literature DB >> 14751762

The role of Toll-like receptors in combating mycobacteria.

Stephan R Krutzik1, Robert L Modlin.   

Abstract

In the battle against infections with mycobacteria, the body employs components of both the innate and adaptive arms of the immune system. Toll-like receptors (TLRs) mediate the activation of cells of the innate immune system leading to dynamic functions including direct anti-microbial activity, induction of cytokine secretion, triggering dendritic cell maturation, and triggering apoptosis. Furthermore, TLR activation is capable of modulating the adaptive immune response with a bias towards a Th1 T-cell response. However, the activation of TLRs by mycobacteria may also provide a means of immune evasion. Therefore, the modulation of TLR activation can influence the ability to properly destroy invading pathogens such as mycobacteria.

Mesh:

Substances:

Year:  2004        PMID: 14751762     DOI: 10.1016/j.smim.2003.10.005

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  40 in total

1.  Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2.

Authors:  Christina L Lancioni; Qing Li; Jeremy J Thomas; XueDong Ding; Bonnie Thiel; Michael G Drage; Nicole D Pecora; Assem G Ziady; Samuel Shank; Clifford V Harding; W Henry Boom; Roxana E Rojas
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Dichotomous role of the macrophage in early Mycobacterium marinum infection of the zebrafish.

Authors:  Hilary Clay; J Muse Davis; Dana Beery; Anna Huttenlocher; Susan E Lyons; Lalita Ramakrishnan
Journal:  Cell Host Microbe       Date:  2007-07-12       Impact factor: 21.023

Review 3.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

4.  Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.

Authors:  C-S Yang; J-S Lee; S-B Jung; J-H Oh; C-H Song; H-J Kim; J-K Park; T-H Paik; E-K Jo
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

5.  N-(2-hydroxy phenyl) acetamide: a novel suppressor of Toll-like receptors (TLR-2 and TLR-4) in adjuvant-induced arthritic rats.

Authors:  Kahkashan Perveen; Farina Hanif; Huma Jawed; Siddiqua Jamall; Shabana Usman Simjee
Journal:  Mol Cell Biochem       Date:  2014-05-21       Impact factor: 3.396

6.  The Mycobacterium tuberculosis SecA2 system subverts phagosome maturation to promote growth in macrophages.

Authors:  Jonathan Tabb Sullivan; Ellen F Young; Jessica R McCann; Miriam Braunstein
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

Review 7.  Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets.

Authors:  Vikas Mishra; Jaspreet Banga; Patricia Silveyra
Journal:  Pharmacol Ther       Date:  2017-08-23       Impact factor: 12.310

8.  TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4.

Authors:  Toshihiro Ito; Matthew Schaller; Cory M Hogaboam; Theodore J Standiford; Matyas Sandor; Nicholas W Lukacs; Stephen W Chensue; Steven L Kunkel
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

9.  Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the Toll-like receptor 2-NF-kappaB and -Jun N-terminal kinase signaling pathways.

Authors:  Patricia Méndez-Samperio; Artemisa Trejo; Aline Pérez
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

10.  Polymorphic variation in TIRAP is not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some ethnic groups.

Authors:  Shobana Rebecca Dissanayeke; Samuel Levin; Sandra Pienaar; Kathryn Wood; Brian Eley; David Beatty; Howard Henderson; Suzanne Anderson; Michael Levin
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.